|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
SI1523496T1
(sl)
|
2002-07-18 |
2011-11-30 |
Merus B V |
Rekombinantno proizvajanje zmesi protiteles
|
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
|
WO2007109321A2
(en)
|
2006-03-20 |
2007-09-27 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
DK2006381T3
(en)
|
2006-03-31 |
2016-02-22 |
Chugai Pharmaceutical Co Ltd |
PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
|
|
US7750124B2
(en)
|
2006-09-29 |
2010-07-06 |
Oncomed Pharmaceuticals, Inc. |
Anti-human DLL4 antibodies and compositions
|
|
AU2008234248C1
(en)
|
2007-03-29 |
2015-01-22 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
JP5931336B2
(ja)
|
2007-07-02 |
2016-06-08 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
がんを処置および診断するための組成物および方法
|
|
CA2698343C
(en)
|
2007-09-04 |
2018-06-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
|
DK2202245T3
(en)
|
2007-09-26 |
2016-11-21 |
Chugai Pharmaceutical Co Ltd |
A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
|
|
EP2740490A1
(en)
*
|
2007-10-03 |
2014-06-11 |
Cornell University |
Treatment of proliferative disorders using antibodies to PSMA
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
EP2398504B1
(en)
|
2009-02-17 |
2018-11-28 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
|
DK2417156T3
(en)
|
2009-04-07 |
2015-03-02 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
CN102459346B
(zh)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
CA2781519A1
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
US20110172398A1
(en)
*
|
2009-10-02 |
2011-07-14 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules for anti-angiogenesis therapy
|
|
EP3485908B1
(en)
|
2009-10-16 |
2021-08-18 |
Mereo BioPharma 5, Inc. |
Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
|
|
US8772459B2
(en)
|
2009-12-02 |
2014-07-08 |
Imaginab, Inc. |
J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
CN110066339A
(zh)
|
2010-04-20 |
2019-07-30 |
根马布股份公司 |
含异二聚体抗体fc的蛋白及其制备方法
|
|
DK2560683T4
(da)
|
2010-04-23 |
2022-08-29 |
Hoffmann La Roche |
Fremstilling af heteromultimeriske proteiner
|
|
ES2659406T3
(es)
|
2010-05-06 |
2018-03-15 |
Novartis Ag |
Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
|
|
US9290573B2
(en)
|
2010-05-06 |
2016-03-22 |
Novartis Ag |
Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
TR201802772T4
(tr)
|
2010-11-17 |
2018-03-21 |
Chugai Pharmaceutical Co Ltd |
Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
|
|
LT2647707T
(lt)
|
2010-11-30 |
2018-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Citotoksiškumą indukuojantis terapinis agentas
|
|
AR085091A1
(es)
|
2011-01-26 |
2013-09-11 |
Kolltan Pharmaceuticals Inc |
Anticuerpos anti-kit y sus usos
|
|
US10689447B2
(en)
*
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
CN103403025B
(zh)
|
2011-02-28 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
单价抗原结合蛋白
|
|
JP5764677B2
(ja)
|
2011-02-28 |
2015-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合タンパク質
|
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
|
ES2608835T3
(es)
|
2011-04-13 |
2017-04-17 |
Bristol-Myers Squibb Company |
Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
|
|
SG194510A1
(en)
|
2011-04-22 |
2013-12-30 |
Emergent Product Dev Seattle |
Prostate-specific membrane antigen binding proteins and related compositionsand methods
|
|
US20140255405A1
(en)
*
|
2011-05-27 |
2014-09-11 |
Dutalys |
Removal of Monomeric Targets
|
|
US9260519B2
(en)
|
2011-06-17 |
2016-02-16 |
President And Fellows Of Harvard College |
Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
EP2543680A1
(en)
*
|
2011-07-07 |
2013-01-09 |
Centre National de la Recherche Scientifique |
Multispecific mutated antibody Fab fragments
|
|
CN106167526A
(zh)
|
2011-07-15 |
2016-11-30 |
昂考梅德药品有限公司 |
Rspo结合剂和其应用
|
|
WO2013026839A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
AU2015268749B2
(en)
*
|
2011-09-23 |
2017-05-25 |
Oncomed Pharmaceuticals, Inc. |
VEGF/DLL4 binding agents and uses thereof
|
|
HRP20190044T1
(hr)
*
|
2011-09-23 |
2019-02-22 |
Oncomed Pharmaceuticals, Inc. |
Agensi koji vežu vegf/dll4 i njihove uporabe
|
|
SG11201401422VA
(en)
|
2011-10-27 |
2014-09-26 |
Genmab As |
Production of heterodimeric proteins
|
|
US11851476B2
(en)
|
2011-10-31 |
2023-12-26 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
|
MX2014005411A
(es)
|
2011-11-04 |
2015-02-12 |
Novartis Ag |
Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
AU2012340826A1
(en)
|
2011-11-21 |
2014-05-29 |
Genentech, Inc. |
Purification of anti-c-met antibodies
|
|
MX350957B
(es)
|
2011-11-23 |
2017-09-27 |
Medimmune Llc |
Moleculas de union especificas para her3 y usos de las mismas.
|
|
RU2693264C2
(ru)
|
2012-02-03 |
2019-07-01 |
Ф.Хоффман-Ля Рош Аг |
Молекулы биспецифических антител и т-клетки, трансфецированные антигеном, и их применение в медицине
|
|
PE20142422A1
(es)
|
2012-04-05 |
2015-01-21 |
Hoffmann La Roche |
Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
|
|
ES2743399T3
(es)
|
2012-04-20 |
2020-02-19 |
Merus Nv |
Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
|
|
US9090694B2
(en)
|
2012-04-30 |
2015-07-28 |
Janssen Biotech, Inc. |
ST2L antibody antagonists
|
|
WO2013184912A2
(en)
|
2012-06-06 |
2013-12-12 |
Oncomed Pharmaceuticals, Inc. |
Binding agents that modulate the hippo pathway and uses thereof
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
CN104736174B
(zh)
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
具有三重突变的二聚体蛋白质
|
|
CA2878868A1
(en)
*
|
2012-07-13 |
2014-01-16 |
Austin L. Gurney |
Rspo3 binding agents and uses thereof
|
|
SG11201500489YA
(en)
|
2012-07-25 |
2015-02-27 |
Kolltan Pharmaceuticals Inc |
Anti-kit antibodies and uses thereof
|
|
PL3489261T3
(pl)
|
2012-08-24 |
2021-08-16 |
The Regents Of The University Of California |
Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
|
|
US10358492B2
(en)
|
2012-09-27 |
2019-07-23 |
Merus N.V. |
Bispecific IgG antibodies as T cell engagers
|
|
RU2015117393A
(ru)
|
2012-10-08 |
2016-12-10 |
Роше Гликарт Аг |
Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
|
|
WO2014062659A2
(en)
*
|
2012-10-15 |
2014-04-24 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating ocular diseases
|
|
AU2013337811A1
(en)
|
2012-10-31 |
2015-05-14 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a DLL4 antagonist
|
|
EP2727941A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Method for the production of multispecific antibodies
|
|
EP2727943A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Trispecific antibodies against human EGFR, HER2 and HER3
|
|
EP2914629A1
(en)
|
2012-11-05 |
2015-09-09 |
MAB Discovery GmbH |
Method for the production of multispecific antibodies
|
|
EP2727942A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Bispecific antibodies against human EGFR, HER2, and HER3
|
|
BR112015010436A2
(pt)
|
2012-11-07 |
2017-08-22 |
Pfizer |
Anticorpos anti-notch3 e conjugados anticorpo-fármaco
|
|
US20170275367A1
(en)
|
2012-11-21 |
2017-09-28 |
Janssen Biotech, Inc. |
Bispecific EGFR/C-Met Antibodies
|
|
PL2922872T3
(pl)
|
2012-11-21 |
2019-03-29 |
Janssen Biotech, Inc. |
Bispecyficzne przeciwciała przeciwko egfr/c-met
|
|
JP6144771B2
(ja)
*
|
2012-11-21 |
2017-06-07 |
ファームアブシン インコーポレイテッド |
Ｖｅｇｆｒ−２とｄｌｌ４を標的とする二重標的抗体及びこれを含む薬学的組成物
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
KR102545617B1
(ko)
|
2012-11-28 |
2023-06-20 |
자임워크스 비씨 인코포레이티드 |
가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
|
|
US9327014B2
(en)
|
2012-12-04 |
2016-05-03 |
Oncomed Pharmaceuticals, Inc. |
Immunotherapy with binding agents
|
|
KR20200024345A
(ko)
|
2013-01-10 |
2020-03-06 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
|
US10047163B2
(en)
|
2013-02-08 |
2018-08-14 |
Abbvie Stemcentrx Llc |
Multispecific constructs
|
|
ES2870802T3
(es)
|
2013-02-12 |
2021-10-27 |
Bristol Myers Squibb Co |
Métodos de replegado de proteínas a elevado pH
|
|
US10183967B2
(en)
|
2013-02-12 |
2019-01-22 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
EA201891502A1
(ru)
|
2013-02-26 |
2018-12-28 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
|
RU2015140915A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
|
US9944700B2
(en)
|
2013-03-13 |
2018-04-17 |
Novartis Ag |
Notch2 binding molecules for treating respiratory diseases
|
|
CA2900955A1
(en)
*
|
2013-03-14 |
2014-10-02 |
Oncomed Pharmaceuticals, Inc. |
Met-binding agents and uses thereof
|
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
CN105358575B
(zh)
|
2013-03-15 |
2020-09-22 |
詹森生物科技公司 |
干扰素α和ω抗体拮抗剂
|
|
KR20160006168A
(ko)
|
2013-03-18 |
2016-01-18 |
바이오서오엑스 프로덕스 비.브이. |
인간화 항-cd134(ox40) 항체 및 이의 용도
|
|
JP2016528167A
(ja)
|
2013-04-29 |
2016-09-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ヒトＦｃＲｎ結合改変抗体及び使用方法
|
|
KR102266819B1
(ko)
|
2013-04-29 |
2021-06-18 |
에프. 호프만-라 로슈 아게 |
Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
|
|
TWI653243B
(zh)
|
2013-04-29 |
2019-03-11 |
赫孚孟拉羅股份公司 |
遏止ＦｃＲｎ結合之抗ＩＧＦ－１Ｒ抗體及其治療血管性眼疾之用途
|
|
ME03675B
(me)
|
2013-07-05 |
2020-10-20 |
Genmab As |
Humanizovana ili himerna anтi-cd3 antiтela
|
|
CN105518028B
(zh)
*
|
2013-07-09 |
2019-08-13 |
Abl生物公司 |
与dll4和vegf特异性结合的新型双靶向蛋白及其用途
|
|
WO2015048008A2
(en)
|
2013-09-24 |
2015-04-02 |
Medimmune, Llc |
Binding molecules specific for her3 and uses thereof
|
|
ES2881306T3
(es)
|
2013-09-27 |
2021-11-29 |
Chugai Pharmaceutical Co Ltd |
Método para la producción de heteromultímeros de polipéptidos
|
|
RU2016115866A
(ru)
|
2013-10-11 |
2017-11-16 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
|
|
LT3065774T
(lt)
|
2013-11-06 |
2021-09-10 |
Janssen Biotech, Inc. |
Anti-ccl17 antikūnai
|
|
KR102357961B1
(ko)
|
2013-12-17 |
2022-02-08 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
|
CA2932958A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Humanized anti-tau(ps422) antibodies and methods of use
|
|
PL3089996T3
(pl)
|
2014-01-03 |
2021-12-13 |
F. Hoffmann-La Roche Ag |
Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
|
|
BR112016015589A2
(pt)
|
2014-01-06 |
2017-10-31 |
Hoffmann La Roche |
módulos de trânsito monovalentes para a barreira hematoencefálica
|
|
BR112016016416A2
(pt)
|
2014-01-15 |
2017-10-03 |
Hoffmann La Roche |
VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
SG11201607109QA
(en)
|
2014-02-28 |
2016-09-29 |
Merus Nv |
Antibodies that bind egfr and erbb3
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
SI3110849T1
(sl)
|
2014-02-28 |
2021-01-29 |
Merus N.V. |
Protitelo, ki veže ERBB-2 in ERBB-3
|
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
EP3126389B1
(en)
|
2014-04-02 |
2024-10-23 |
F. Hoffmann-La Roche AG |
Method for detecting multispecific antibody light chain mispairing
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
PT3126521T
(pt)
*
|
2014-04-04 |
2019-06-27 |
Crown Bioscience Inc Taicang |
Gene de fusão hnf4g-rspo2
|
|
MX380176B
(es)
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
WO2015157634A1
(en)
|
2014-04-11 |
2015-10-15 |
Kolltan Pharmaceuticals, Inc. |
Anti-erbb antibodies and methods of use thereof
|
|
ES2955736T3
(es)
|
2014-05-06 |
2023-12-05 |
Hoffmann La Roche |
Producción de proteínas heteromultiméricas usando células de mamífero
|
|
US11505605B2
(en)
|
2014-05-13 |
2022-11-22 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
|
CN106659782B
(zh)
|
2014-05-23 |
2021-11-09 |
塞尔德克斯医疗公司 |
一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体
|
|
EA201692476A1
(ru)
|
2014-05-28 |
2017-07-31 |
Займворкс Инк. |
Модифицированные антигенсвязывающие полипептидные конструкции и их применение
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
WO2015197736A1
(en)
|
2014-06-26 |
2015-12-30 |
F. Hoffmann-La Roche Ag |
Anti-brdu antibodies and methods of use
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
ES2774428T3
(es)
|
2014-07-11 |
2020-07-21 |
Genmab As |
Anticuerpos que se unen a AXL
|
|
WO2016014565A2
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
BR112017001242A2
(pt)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico a cd33
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
KR102411972B1
(ko)
|
2014-08-04 |
2022-06-23 |
에프. 호프만-라 로슈 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
|
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
RS60305B1
(sr)
|
2014-09-05 |
2020-07-31 |
Janssen Pharmaceutica Nv |
Agensi koji vezuju cd123 i njihove upotrebe
|
|
MY192918A
(en)
|
2014-09-09 |
2022-09-15 |
Janssen Biotech Inc |
Combination therapies with anti-cd38 antibodies
|
|
JP6796059B2
(ja)
|
2014-09-12 |
2020-12-02 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
Ｗｎｔシグナリングアゴニスト分子
|
|
EP3193935A4
(en)
|
2014-09-16 |
2018-03-21 |
Oncomed Pharmaceuticals, Inc. |
Treatment of fibrotic diseases
|
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
EP3204415B1
(en)
|
2014-10-09 |
2020-06-17 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and ror1
|
|
MX389663B
(es)
|
2014-10-14 |
2025-03-20 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
|
|
MX382902B
(es)
|
2014-10-31 |
2025-03-13 |
Oncomed Pharm Inc |
Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
|
|
SI3215528T1
(sl)
|
2014-11-06 |
2019-11-29 |
Hoffmann La Roche |
Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
|
|
EP3215524B1
(en)
|
2014-11-06 |
2021-01-13 |
F.Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
LT3789402T
(lt)
|
2014-11-20 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
RS60615B1
(sr)
|
2014-11-20 |
2020-08-31 |
Hoffmann La Roche |
Zajednički laki lanci i postupci upotrebe
|
|
CN107074955B
(zh)
|
2014-11-20 |
2021-06-22 |
豪夫迈·罗氏有限公司 |
针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
|
EP3227338A4
(en)
|
2014-12-04 |
2018-05-16 |
Janssen Biotech, Inc. |
Anti-cd38 antibodies for treatment of acute myeloid leukemia
|
|
DK3233907T3
(da)
|
2014-12-19 |
2021-06-07 |
Genmab As |
Bispecifikke heterodimeriske proteiner hos gnavere
|
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
IL254817B2
(en)
|
2015-04-08 |
2023-12-01 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
JP7103751B6
(ja)
*
|
2015-04-28 |
2022-08-15 |
ザイムワークス，インコーポレイテッド |
修飾された抗原結合ポリペプチド構築物及びその使用
|
|
CA2985125A1
(en)
|
2015-05-06 |
2016-11-10 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
|
CR20170526A
(es)
|
2015-05-20 |
2018-04-03 |
Janssen Biotech Inc |
ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
|
|
US10323094B2
(en)
|
2015-06-16 |
2019-06-18 |
Genentech, Inc. |
Humanized and affinity matured antibodies to FcRH5 and methods of use
|
|
MY192978A
(en)
|
2015-06-22 |
2022-09-20 |
Janssen Biotech Inc |
Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
|
|
HUE066300T2
(hu)
|
2015-06-24 |
2024-07-28 |
Janssen Biotech Inc |
Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel
|
|
ES2809728T3
(es)
|
2015-06-24 |
2021-03-05 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
|
EP3345928B1
(en)
|
2015-07-10 |
2020-06-24 |
Merus N.V. |
Human cd3 binding antibody
|
|
LT3319993T
(lt)
|
2015-07-10 |
2020-05-11 |
Genmab A/S |
Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti
|
|
IL256562B2
(en)
|
2015-07-15 |
2024-07-01 |
Genmab As |
Human CD3 antibodies or chimeras
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
CA2994825A1
(en)
|
2015-08-05 |
2017-02-09 |
Janssen Biotech, Inc. |
Anti-cd154 antibodies and methods of using them
|
|
ES3020458T3
(en)
|
2015-08-07 |
2025-05-22 |
Imaginab Inc |
Antigen binding constructs to target molecules
|
|
PT3337824T
(pt)
|
2015-08-17 |
2020-09-10 |
Janssen Pharmaceutica Nv |
Anticorpos anti-bcma, moléculas de ligação a antigénio biespecíficas que ligam bcma e cd3, e suas utilizações
|
|
BR112017026543A2
(pt)
|
2015-08-26 |
2018-08-14 |
Bison Therapeutics Inc |
plataforma de anticorpo multiespecífico e métodos relacionados
|
|
HK1258125A1
(zh)
|
2015-09-04 |
2019-11-08 |
The California Institute For Biomedical Research |
胰岛素免疫球蛋白融合蛋白
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
WO2017053705A1
(en)
|
2015-09-23 |
2017-03-30 |
Oncomed Pharmaceuticals, Inc. |
Methods and compositions for treatment of cancer
|
|
MX2018003905A
(es)
|
2015-09-30 |
2018-09-06 |
Janssen Biotech Inc |
Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso.
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
EP3356417A1
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
CN107949574A
(zh)
|
2015-10-02 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
双特异性t细胞活化性抗原结合分子
|
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
EP3356821B1
(en)
|
2015-10-02 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Cellular based fret assay for the determination of simultaneous binding
|
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
CN107849137B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗ceaxcd3 t细胞活化性抗原结合分子
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
PE20180773A1
(es)
|
2015-10-02 |
2018-05-07 |
Hoffmann La Roche |
Anticuerpos biespecificos para pd1 y tim3
|
|
BR112018008068A2
(en)
|
2015-10-23 |
2018-11-13 |
Merus N.V. |
binding molecules that inhibit cancer growth
|
|
CN114891102A
(zh)
|
2015-10-29 |
2022-08-12 |
豪夫迈·罗氏有限公司 |
抗变体Fc区抗体及使用方法
|
|
EP3371220A2
(en)
|
2015-11-02 |
2018-09-12 |
Janssen Pharmaceutica NV |
Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
|
|
PL3827845T3
(pl)
|
2015-11-03 |
2022-07-11 |
Janssen Biotech, Inc. |
Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
|
|
SI3370768T1
(sl)
|
2015-11-03 |
2022-04-29 |
Janssen Biotech, Inc. |
Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
|
|
MX2018006333A
(es)
|
2015-12-01 |
2018-08-01 |
Genmab Bv |
Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
|
|
IL257696B2
(en)
|
2015-12-09 |
2024-11-01 |
Hoffmann La Roche |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
EP3390453A2
(en)
|
2015-12-17 |
2018-10-24 |
Janssen Biotech, Inc. |
Antibodies specifically binding hla-dr and their uses
|
|
JP2019502695A
(ja)
|
2015-12-17 |
2019-01-31 |
ノバルティス アーゲー |
ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
|
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
|
JP6954842B2
(ja)
|
2015-12-25 |
2021-10-27 |
中外製薬株式会社 |
増強された活性を有する抗体及びその改変方法
|
|
JP7219005B2
(ja)
|
2015-12-28 |
2023-02-07 |
中外製薬株式会社 |
Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
EP3408671B1
(en)
*
|
2016-01-25 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Methods for assaying t-cell dependent bispecific antibodies
|
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
EP3431102A4
(en)
|
2016-03-14 |
2019-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
|
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
FI3433280T3
(fi)
|
2016-03-22 |
2023-06-06 |
Hoffmann La Roche |
Proteaasin aktivoimia t-solubispesifisiä molekyylejä
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
SI3443096T1
(sl)
|
2016-04-15 |
2023-07-31 |
Novartis Ag |
Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev
|
|
JP7320943B2
(ja)
|
2016-04-28 |
2023-08-04 |
中外製薬株式会社 |
抗体含有製剤
|
|
JP6675017B2
(ja)
|
2016-05-02 |
2020-04-01 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
コントースボディ−単鎖標的結合物質
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
AU2018276419A1
(en)
|
2016-06-02 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
|
|
EP3464375A2
(en)
|
2016-06-02 |
2019-04-10 |
Novartis AG |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
CA3029003A1
(en)
|
2016-06-27 |
2018-01-04 |
The Regents Of The University Of California |
Cancer treatment combinations
|
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
|
|
WO2018007314A1
(en)
|
2016-07-04 |
2018-01-11 |
F. Hoffmann-La Roche Ag |
Novel antibody format
|
|
UA128304C2
(uk)
|
2016-07-14 |
2024-06-05 |
Ґенмаб А/С |
Мультиспецифічне антитіло до cd40 і cd137
|
|
CN120285179A
(zh)
|
2016-07-15 |
2025-07-11 |
诺华股份有限公司 |
使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
|
|
TWI781108B
(zh)
|
2016-07-20 |
2022-10-21 |
比利時商健生藥品公司 |
抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
|
|
IL264486B2
(en)
|
2016-07-28 |
2025-04-01 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
SG11201900885VA
(en)
|
2016-08-01 |
2019-02-27 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
SG11201900744SA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
CN109863170B
(zh)
|
2016-08-12 |
2024-08-16 |
詹森生物科技公司 |
具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子
|
|
WO2018060301A1
(en)
|
2016-09-30 |
2018-04-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against cd3
|
|
JP6785372B2
(ja)
|
2016-09-30 |
2020-11-18 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
JOP20190097A1
(ar)
|
2016-10-27 |
2019-04-28 |
Janssen Pharmaceutica Nv |
الجلوبولينات المناعية واستخداماتها
|
|
EP3535291A1
(en)
|
2016-11-01 |
2019-09-11 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
WO2018094282A1
(en)
*
|
2016-11-18 |
2018-05-24 |
The Regents Of The University Of California |
Engineered antibodies and uses thereof
|
|
MX2019005772A
(es)
|
2016-11-23 |
2019-10-02 |
Bioverativ Therapeutics Inc |
Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x.
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
KR20250140128A
(ko)
|
2017-02-10 |
2025-09-24 |
젠맵 비. 브이 |
폴리펩티드 변이체 및 그의 용도
|
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
TW201834688A
(zh)
*
|
2017-02-24 |
2018-10-01 |
日商中外製藥股份有限公司 |
藥學組成物、抗原結合分子、治療方法以及篩選方法
|
|
WO2018158719A1
(en)
|
2017-03-02 |
2018-09-07 |
Novartis Ag |
Engineered heterodimeric proteins
|
|
CN116836285A
(zh)
|
2017-03-09 |
2023-10-03 |
健玛保 |
针对pd-l1的抗体
|
|
SG11201908127WA
(en)
|
2017-03-10 |
2019-10-30 |
Hoffmann La Roche |
Method for producing multispecific antibodies
|
|
CA3058343A1
(en)
|
2017-03-31 |
2018-10-04 |
Merus N.V. |
Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
|
|
EP3601354A1
(en)
|
2017-03-31 |
2020-02-05 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
|
BR112019018767A2
(pt)
|
2017-04-03 |
2020-05-05 |
Hoffmann La Roche |
anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, usos, método para tratar uma doença em um indivíduo e invenção
|
|
WO2018184965A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
|
PT3606946T
(pt)
|
2017-04-03 |
2022-10-17 |
Hoffmann La Roche |
Imunoconjugados de um anticorpo anti-pd-1 com uma il-2 mutante ou com il-15
|
|
WO2018187227A1
(en)
|
2017-04-03 |
2018-10-11 |
Concologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
|
CN113527499A
(zh)
*
|
2017-04-09 |
2021-10-22 |
轩竹生物科技有限公司 |
有共同轻链的双互补位和多互补位抗体和使用方法
|
|
BR112019021411A2
(pt)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
CN108866635B
(zh)
*
|
2017-05-09 |
2021-11-26 |
安升（上海）医药科技有限公司 |
多特异性蛋白药物及其文库、以及制备方法和应用
|
|
US12195551B2
(en)
|
2017-05-17 |
2025-01-14 |
Merus N.V. |
Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
MX2019014577A
(es)
|
2017-06-05 |
2020-07-29 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y metodos de uso.
|
|
BR112019025583A2
(pt)
|
2017-06-05 |
2020-06-16 |
Janssen Biotech, Inc. |
Anticorpos multiespecíficos geneticamente modificados e outras proteínas multiméricas com mutações assimétricas na região ch2-ch3
|
|
CN111328335A
(zh)
|
2017-06-07 |
2020-06-23 |
根马布私人有限公司 |
基于突变igg六聚体的治疗性抗体
|
|
EP3641812A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
AU2018292618A1
(en)
|
2017-06-27 |
2019-12-19 |
Novartis Ag |
Dosage regimens for anti-TIM-3 antibodies and uses thereof
|
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
|
EP3652209A2
(en)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics LLC |
Agonist antibodies that bind human cd137 and uses thereof
|
|
KR20250025039A
(ko)
|
2017-07-20 |
2025-02-20 |
노파르티스 아게 |
항-lag-3 항체의 투여 요법 및 그의 용도
|
|
JP7290013B2
(ja)
|
2017-08-04 |
2023-06-13 |
ジェンマブ エー／エス |
Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用
|
|
HUE071182T2
(hu)
|
2017-08-09 |
2025-08-28 |
Merus Nv |
EGFR és CMET kötõ antitestek
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
UA128389C2
(uk)
|
2017-09-29 |
2024-07-03 |
Чугаі Сейяку Кабусікі Кайся |
Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт
|
|
CN111246885B
(zh)
|
2017-10-20 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
从单特异性抗体生成多特异性抗体的方法
|
|
MX2020004100A
(es)
|
2017-10-30 |
2020-07-24 |
Hoffmann La Roche |
Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
JP7092881B2
(ja)
|
2017-11-01 |
2022-06-28 |
エフ．ホフマン－ラ ロシュ アーゲー |
ＴｒｉＦａｂコントースボディ
|
|
AU2018361430B2
(en)
|
2017-11-01 |
2025-08-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody variant and isoform with lowered biological activity
|
|
CN111295392A
(zh)
|
2017-11-01 |
2020-06-16 |
豪夫迈·罗氏有限公司 |
Compbody–多价靶结合物
|
|
EP3703746A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Novel tnf family ligand trimer-containing antigen binding molecules
|
|
SG11202002903XA
(en)
|
2017-11-01 |
2020-04-29 |
Hoffmann La Roche |
Bispecific 2+1 contorsbodies
|
|
AU2018368731A1
(en)
|
2017-11-16 |
2020-05-14 |
Novartis Ag |
Combination therapies
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
JP6522727B2
(ja)
*
|
2017-12-15 |
2019-05-29 |
矢崎総業株式会社 |
メッキ繊維及びワイヤハーネス
|
|
CA3085596A1
(en)
|
2017-12-19 |
2019-06-27 |
Surrozen, Inc. |
Anti-frizzled antibodies and methods of use
|
|
US11746150B2
(en)
|
2017-12-19 |
2023-09-05 |
Surrozen Operating, Inc. |
Anti-LRP5/6 antibodies and methods of use
|
|
US11773171B2
(en)
|
2017-12-19 |
2023-10-03 |
Surrozen Operating, Inc. |
WNT surrogate molecules and uses thereof
|
|
CN111527107B
(zh)
|
2017-12-21 |
2024-10-01 |
豪夫迈·罗氏有限公司 |
结合hla-a2/wt1的抗体
|
|
CN111491951B
(zh)
|
2017-12-22 |
2024-05-24 |
豪夫迈·罗氏有限公司 |
通过疏水相互作用色谱法耗尽轻链错配的抗体变体
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
JP2021510740A
(ja)
|
2018-01-24 |
2021-04-30 |
ゲンマブ ビー．ブイ． |
ポリペプチド変種およびそれらの用途
|
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
MX2020007527A
(es)
|
2018-02-06 |
2020-09-09 |
Hoffmann La Roche |
Tratamiento de enfermedades oftalmologicas.
|
|
MX2020008289A
(es)
|
2018-02-08 |
2020-09-25 |
Genentech Inc |
Moleculas biespecificas de union al antigeno y metodos de uso.
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
JP7466442B2
(ja)
|
2018-02-14 |
2024-04-12 |
中外製薬株式会社 |
抗原結合分子および組合せ
|
|
EP3765493A2
(en)
|
2018-03-12 |
2021-01-20 |
Genmab A/S |
Antibodies
|
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
CN108752478B
(zh)
*
|
2018-05-03 |
2021-05-25 |
沣潮医药科技（上海）有限公司 |
全人源抗人EGFR和Notch2/3多特异性抗体、其制备方法及用途
|
|
MX2020011552A
(es)
|
2018-05-03 |
2020-11-24 |
Genmab Bv |
Combinaciones de variantes de anticuerpos y usos de las mismas.
|
|
AU2019270624B2
(en)
|
2018-05-16 |
2024-05-02 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
|
|
AU2019272575A1
(en)
|
2018-05-21 |
2020-12-10 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by NK cells
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
EA202092849A1
(ru)
|
2018-05-24 |
2021-03-16 |
Янссен Байотек, Инк. |
Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
|
|
JOP20200303A1
(ar)
|
2018-05-24 |
2020-11-23 |
Janssen Biotech Inc |
عوامل ربط psma واستخداماتها
|
|
JOP20190116A1
(ar)
|
2018-05-24 |
2019-11-24 |
Janssen Biotech Inc |
الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
|
|
RS66901B1
(sr)
|
2018-05-24 |
2025-07-31 |
Janssen Biotech Inc |
Anti-cd3 antitela i njihova upotreba
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
SG11202011461TA
(en)
|
2018-06-01 |
2020-12-30 |
Compugen Ltd |
Anti-pvrig/anti-tigit bispecific antibodies and methods of use
|
|
AU2019284911A1
(en)
|
2018-06-13 |
2020-12-17 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
US20210238268A1
(en)
|
2018-06-19 |
2021-08-05 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
EP3810194A1
(en)
|
2018-06-22 |
2021-04-28 |
Genmab Holding B.V. |
Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US20240254252A1
(en)
|
2018-07-13 |
2024-08-01 |
Genmab A/S |
Trogocytosis-mediated therapy using cd38 antibodies
|
|
CA3106146A1
(en)
|
2018-07-13 |
2020-01-16 |
Genmab A/S |
Variants of cd38 antibody and uses thereof
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
JP7523349B2
(ja)
|
2018-08-29 |
2024-07-26 |
中外製薬株式会社 |
抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法
|
|
MA53812A
(fr)
|
2018-10-04 |
2021-08-11 |
Genmab Holding B V |
Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
|
|
KR102467349B1
(ko)
|
2018-10-29 |
2022-11-16 |
에프. 호프만-라 로슈 아게 |
항체 제형
|
|
CN120983617A
(zh)
|
2018-11-06 |
2025-11-21 |
健玛保 |
抗体配制剂
|
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
|
JP2022513708A
(ja)
|
2018-12-05 |
2022-02-09 |
モルフォシス・アーゲー |
多重特異性抗原結合分子
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
JP2022513255A
(ja)
|
2018-12-20 |
2022-02-07 |
ノバルティス アーゲー |
ＨＤＭ２－ｐ５３相互作用阻害剤とＢＣＬ２阻害剤との組み合わせ及び癌を処置するためのその使用
|
|
TWI881476B
(zh)
|
2018-12-21 |
2025-04-21 |
瑞士商赫孚孟拉羅股份公司 |
結合cd3之抗體
|
|
SG11202106393SA
(en)
|
2018-12-24 |
2021-07-29 |
Sanofi Sa |
Pseudofab-based multispecific binding proteins
|
|
US20220073630A1
(en)
|
2018-12-28 |
2022-03-10 |
Hoffmann-La Roche, Inc. |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
AU2020208828A1
(en)
|
2019-01-15 |
2021-08-05 |
Janssen Biotech, Inc. |
Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
|
PE20211977A1
(es)
|
2019-01-18 |
2021-10-05 |
Janssen Biotech Inc |
Receptores de antigenos quimericos de gprc5d y celulas que los expresan
|
|
US20220064278A1
(en)
|
2019-01-23 |
2022-03-03 |
Janssen Biotech, Inc. |
Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
ES2982474T3
(es)
|
2019-02-15 |
2024-10-16 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
|
|
GB2598218B
(en)
|
2019-02-21 |
2024-05-08 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
EP3927747A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CA3131016A1
(en)
|
2019-02-21 |
2020-08-27 |
Andreas Loew |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
US20220088075A1
(en)
|
2019-02-22 |
2022-03-24 |
The Trustees Of The University Of Pennsylvania |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
US11459391B2
(en)
|
2019-02-26 |
2022-10-04 |
Janssen Biotech, Inc. |
Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
|
|
MA55305A
(fr)
|
2019-03-11 |
2022-01-19 |
Janssen Biotech Inc |
Anticorps bispécifiques anti-v béta 17/anti-cd123
|
|
CN113825765A
(zh)
|
2019-03-14 |
2021-12-21 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
|
MA55282A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
|
|
CA3133388A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
|
CA3133383A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
|
PH12021552414A1
(en)
|
2019-03-29 |
2022-07-25 |
Atarga Llc |
Anti fgf23 antibody
|
|
CN113677701B
(zh)
|
2019-03-29 |
2025-02-07 |
豪夫迈·罗氏有限公司 |
产生亲合结合多特异性抗体的方法
|
|
CN113646622B
(zh)
|
2019-03-29 |
2024-11-12 |
豪夫迈·罗氏有限公司 |
用于多价分子的功能分析的基于spr的结合测定
|
|
KR20220002899A
(ko)
|
2019-04-19 |
2022-01-07 |
얀센 바이오테크 인코포레이티드 |
항-psma/cd3 항체로 전립선암을 치료하는 방법
|
|
JP2022531128A
(ja)
|
2019-04-25 |
2022-07-06 |
エフ．ホフマン－ラ ロシュ アーゲー |
ポリペプチド鎖交換による抗体由来ポリペプチドの生成
|
|
JP7688584B2
(ja)
|
2019-04-25 |
2025-06-04 |
エフ． ホフマン－ラ ロシュ アーゲー |
ポリペプチド鎖の交換により活性化される治療用多重特異性ポリペプチド
|
|
TW202106713A
(zh)
|
2019-04-25 |
2021-02-16 |
瑞士商赫孚孟拉羅股份公司 |
具延長半衰期之可活化治療性多特異性多肽
|
|
KR20220017892A
(ko)
|
2019-05-08 |
2022-02-14 |
얀센 바이오테크 인코포레이티드 |
T세포 매개 면역의 조절을 위한 물질 및 방법
|
|
US20220315661A1
(en)
|
2019-05-09 |
2022-10-06 |
Genmab B.V. |
Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
|
|
EP3969907B1
(en)
|
2019-05-13 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Interference-suppressed pharmacokinetic immunoassay
|
|
JOP20210304A1
(ar)
|
2019-05-14 |
2023-01-30 |
Janssen Biotech Inc |
علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
|
|
WO2020245676A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
|
AU2020291208A1
(en)
*
|
2019-06-11 |
2022-01-06 |
Antlera Therapeutics Inc. |
Multivalent FZD and Wnt binding molecules and uses thereof
|
|
CA3140297A1
(en)
|
2019-06-19 |
2020-12-24 |
Simon Auslaender |
Method for the generation of a protein expressing cell by targeted integration using cre mrna
|
|
HUE071032T2
(hu)
|
2019-06-26 |
2025-07-28 |
Hoffmann La Roche |
Emlõs sejtvonalak SIRT-1 gén kiiktatásával
|
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
US12435131B2
(en)
|
2019-07-11 |
2025-10-07 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
|
|
EP3997122A1
(en)
|
2019-07-12 |
2022-05-18 |
Janssen Pharmaceutica NV |
Binding agents and uses thereof
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
US12077585B2
(en)
|
2019-07-26 |
2024-09-03 |
Janssen Biotech, Inc. |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
|
PE20220394A1
(es)
|
2019-07-31 |
2022-03-18 |
Hoffmann La Roche |
Anticuerpos que se fijan a gprc5d
|
|
EP4004045A1
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
|
PH12022550348A1
(en)
|
2019-08-15 |
2022-12-12 |
Janssen Biotech Inc |
Materials and methods for improved single chain variable fragments
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
CN114786680A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
Tim-3抑制剂及其用途
|
|
US20220411529A1
(en)
|
2019-11-06 |
2022-12-29 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
MX2022005983A
(es)
|
2019-11-18 |
2022-09-07 |
Janssen Biotech Inc |
Receptores del antígeno quimérico anti-cd79, células car-t, y usos de estos.
|
|
CA3163104A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
CN110964119A
(zh)
*
|
2019-12-05 |
2020-04-07 |
沣潮医药科技（上海）有限公司 |
抗疟二聚体免疫粘附素、药物组合物和用途
|
|
US20210188990A1
(en)
|
2019-12-11 |
2021-06-24 |
Cilag Gmbh International |
Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
|
|
EP4076663A1
(en)
|
2019-12-18 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Bispecific anti-ccl2 antibodies
|
|
PE20221282A1
(es)
|
2019-12-18 |
2022-09-05 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
US11913945B2
(en)
|
2020-01-02 |
2024-02-27 |
Hoffmann-La Roche Inc. |
Method for determining the amount of a therapeutic antibody in the brain
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
PE20230113A1
(es)
|
2020-01-16 |
2023-01-27 |
Genmab As |
Formulaciones de anticuerpos anti-cd38 y usos de las mismas
|
|
EP4090335A1
(en)
|
2020-01-17 |
2022-11-23 |
Novartis AG |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
US20210222244A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
IL295129A
(en)
|
2020-01-30 |
2022-09-01 |
Umoja Biopharma Inc |
Bispecific transduction enhancer
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
JOP20220184A1
(ar)
|
2020-02-12 |
2023-01-30 |
Janssen Biotech Inc |
علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
BR112022016633A2
(pt)
|
2020-02-27 |
2022-12-13 |
Novartis Ag |
Métodos para produzir células que expressam receptor de antígeno quimérico
|
|
UY40280A
(es)
|
2020-03-13 |
2023-07-31 |
Janssen Biotech Inc |
Dominios de unión a antígeno que se unen a la proteina cd33 de la superficie de células mieloides
|
|
AU2021236906A1
(en)
|
2020-03-18 |
2022-08-18 |
Genmab A/S |
Antibodies binding to B7H4
|
|
EP4135848A2
(en)
|
2020-04-15 |
2023-02-22 |
F. Hoffmann-La Roche AG |
Immunoconjugates
|
|
MX2022012752A
(es)
|
2020-04-15 |
2023-01-16 |
Voyager Therapeutics Inc |
Compuestos de union a tau.
|
|
CN115916840A
(zh)
|
2020-04-16 |
2023-04-04 |
詹森生物科技公司 |
用于监测多特异性分子的形成物的反相高效液相色谱（rp-hplc）的系统、材料和方法
|
|
KR20230028242A
(ko)
|
2020-04-24 |
2023-02-28 |
마렝고 테라퓨틱스, 인크. |
T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
|
|
JP2023524068A
(ja)
|
2020-04-30 |
2023-06-08 |
ブリストル－マイヤーズ スクイブ カンパニー |
サイトカイン関連有害事象を治療する方法
|
|
US20230227570A1
(en)
|
2020-05-08 |
2023-07-20 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
EP4149524A1
(en)
|
2020-05-11 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Combination therapy with modified pbmcs and an immunoconjugate
|
|
IL298046A
(en)
|
2020-05-11 |
2023-01-01 |
Janssen Biotech Inc |
Methods for treating multiple myeloma
|
|
KR20230017841A
(ko)
|
2020-05-27 |
2023-02-06 |
얀센 바이오테크 인코포레이티드 |
Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
|
|
GB202008860D0
(en)
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
|
AU2021291407A1
(en)
|
2020-06-19 |
2022-09-29 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3
|
|
WO2021255143A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and folr1
|
|
AR122657A1
(es)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
Moléculas de unión al dominio fc de activación inmunitaria
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
TWI852680B
(zh)
|
2020-06-19 |
2024-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與 cd3 及 cd19 結合之抗體
|
|
MX2022015852A
(es)
|
2020-06-23 |
2023-01-24 |
Novartis Ag |
Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
PH12023550015A1
(en)
|
2020-07-16 |
2024-03-11 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
EP4185388A1
(en)
|
2020-07-23 |
2023-05-31 |
Genmab B.V. |
A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
TW202221028A
(zh)
|
2020-07-29 |
2022-06-01 |
美商健生生物科技公司 |
包括hla-g抗原結合域之蛋白及其用途
|
|
CN116322776A
(zh)
|
2020-08-03 |
2023-06-23 |
詹森生物科技公司 |
用于病毒治疗剂中的多向生物转运的材料和方法
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2021322046A1
(en)
|
2020-08-06 |
2023-02-02 |
BioNTech SE |
Binding agents for coronavirus S protein
|
|
WO2022035722A1
(en)
|
2020-08-10 |
2022-02-17 |
Janssen Biotech, Inc. |
Materials and methods for producing bioengineered virus specific lymphocytes
|
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
|
CA3190766A1
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
EP4208200A2
(en)
|
2020-09-02 |
2023-07-12 |
Genmab A/S |
Antibody therapy
|
|
BR112023004319A2
(pt)
|
2020-09-10 |
2023-04-04 |
Genmab As |
Método para tratar linfoma difuso de grandes células b
|
|
JP2023541860A
(ja)
|
2020-09-10 |
2023-10-04 |
ジェンマブ エー／エス |
びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
CA3190376A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
CA3190349A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
|
CN116406293A
(zh)
|
2020-09-10 |
2023-07-07 |
健玛保 |
用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
|
|
BR112023004296A2
(pt)
|
2020-09-10 |
2023-04-04 |
Genmab As |
Método para tratar linfoma de célula b grande difusa em um indivíduo humano
|
|
WO2022056197A1
(en)
|
2020-09-11 |
2022-03-17 |
Janssen Biotech, Inc. |
Immune targeting molecules and uses thereof
|
|
WO2022056192A1
(en)
|
2020-09-11 |
2022-03-17 |
Janssen Biotech, Inc. |
Methods and compositions for modulating beta chain mediated immunity
|
|
KR20230068415A
(ko)
|
2020-09-24 |
2023-05-17 |
에프. 호프만-라 로슈 아게 |
유전자 녹아웃을 갖는 포유류 세포주
|
|
CN116438198A
(zh)
|
2020-10-02 |
2023-07-14 |
健玛保 |
能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体
|
|
UY39467A
(es)
|
2020-10-13 |
2022-04-29 |
Janssen Biotech Inc |
Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii
|
|
TW202233672A
(zh)
|
2020-10-22 |
2022-09-01 |
美商健生生物科技公司 |
包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
|
|
TW202233674A
(zh)
|
2020-10-28 |
2022-09-01 |
美商健生生物科技公司 |
用於調節δγ鏈介導之免疫的組成物及方法
|
|
TWI888665B
(zh)
|
2020-11-04 |
2025-07-01 |
美商建南德克公司 |
抗cd20/抗cd3雙特異性抗體之皮下給藥
|
|
US12351643B2
(en)
|
2020-11-04 |
2025-07-08 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
EP4245317A4
(en)
|
2020-11-10 |
2024-11-06 |
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. |
BISPECIFIC ANTIBODY FOR CLAUDIN 18A2 AND CD3 AND APPLICATION OF BISPECIFIC ANTIBODY
|
|
CA3198447A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
PE20240819A1
(es)
|
2020-12-17 |
2024-04-18 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos
|
|
EP4263595A1
(en)
|
2020-12-18 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Precursor proteins and kit for targeted therapy
|
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｘｂｐ１を標的とするオリゴヌクレオチド
|
|
IL304067A
(en)
|
2021-01-06 |
2023-08-01 |
Hoffmann La Roche |
Combined treatment using PD1-LAG3 bispecific antibody and CD20 T cell bispecific antibody
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
AU2022214491A1
(en)
|
2021-01-28 |
2023-09-14 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
|
|
US11639396B2
(en)
|
2021-02-16 |
2023-05-02 |
Janssen Biotech, Inc. |
Antibody binding to a linker peptide
|
|
US20220267438A1
(en)
|
2021-02-16 |
2022-08-25 |
Janssen Pharmaceutica Nv |
Trispecific antibody targeting bcma, gprc5d, and cd3
|
|
EP4295154A1
(en)
|
2021-02-18 |
2023-12-27 |
F. Hoffmann-La Roche AG |
Method for resolving complex, multistep antibody interactions
|
|
WO2022189942A1
(en)
|
2021-03-09 |
2022-09-15 |
Janssen Biotech, Inc. |
Treatment of cancers lacking egfr-activating mutations
|
|
JP2024512386A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェンマブ エー／エス |
非活性化抗体バリアント
|
|
CN117098781A
(zh)
|
2021-03-24 |
2023-11-21 |
詹森生物科技公司 |
靶向cd22和cd79b的抗体
|
|
CA3214307A1
(en)
|
2021-03-24 |
2022-09-29 |
Janssen Biotech, Inc. |
Proteins comprising cd3 antigen binding domains and uses thereof
|
|
MX2023011267A
(es)
|
2021-03-24 |
2023-12-14 |
Janssen Biotech Inc |
Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3.
|
|
WO2022206872A1
(zh)
|
2021-03-31 |
2022-10-06 |
江苏恒瑞医药股份有限公司 |
截短的taci多肽及其融合蛋白和用途
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
|
MX2023012408A
(es)
|
2021-04-30 |
2023-10-31 |
Hoffmann La Roche |
Dosis para tratamiento conjunto con anticuerpo biespecifico anti-cd20/anti-cd3 y conjugado anticuerpo farmaco anti-cd79b.
|
|
TW202244059A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
JP2024519212A
(ja)
|
2021-05-07 |
2024-05-09 |
ジェンマブ エー／エス |
Ｂ７ｈ４およびｃｄ３に結合する二重特異性抗体を含む薬学的組成物
|
|
TW202306990A
(zh)
|
2021-05-12 |
2023-02-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
特異性結合ｒａｎｋｌ和ｎｇｆ的抗原結合分子及其醫藥用途
|
|
CN117120478A
(zh)
|
2021-05-14 |
2023-11-24 |
江苏恒瑞医药股份有限公司 |
一种抗原结合分子
|
|
US12291575B2
(en)
|
2021-05-14 |
2025-05-06 |
Genentech, Inc. |
Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
TW202309094A
(zh)
|
2021-05-18 |
2023-03-01 |
美商健生生物科技公司 |
用於識別癌症患者以進行組合治療之方法
|
|
CA3221735A1
(en)
|
2021-06-18 |
2022-12-22 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
|
US20240262924A1
(en)
|
2021-06-21 |
2024-08-08 |
Genmab A/S |
Combination dosage regime of cd137 and pd-l1 binding agents
|
|
KR20240028452A
(ko)
|
2021-07-02 |
2024-03-05 |
제넨테크, 인크. |
암을 치료하기 위한 방법 및 조성물
|
|
CN117957251A
(zh)
|
2021-07-09 |
2024-04-30 |
詹森生物科技公司 |
用于制备抗tnf抗体组合物的制造方法
|
|
KR20240034215A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체 조성물을 생산하기 위한 제조 방법
|
|
IL309997A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-TNF antibody compositions
|
|
CA3225715A1
(en)
|
2021-07-14 |
2023-01-19 |
Xin Ye |
Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof
|
|
CN117730102A
(zh)
|
2021-07-22 |
2024-03-19 |
豪夫迈·罗氏有限公司 |
异二聚体Fc结构域抗体
|
|
CN117715939A
(zh)
|
2021-07-27 |
2024-03-15 |
莫佛塞斯公司 |
抗原结合分子的组合
|
|
MX2024001214A
(es)
|
2021-07-28 |
2024-02-12 |
Hoffmann La Roche |
Metodos y composiciones para tratar cancer.
|
|
US20250270314A1
(en)
|
2021-08-02 |
2025-08-28 |
Tavotek Biotech (Suzhou) Ltd |
Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
|
|
US20250277051A1
(en)
|
2021-08-02 |
2025-09-04 |
Hangzhou Unogen Biotech, Ltd |
Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
|
|
KR20240051280A
(ko)
|
2021-09-06 |
2024-04-19 |
젠맵 에이/에스 |
Cd27과 결합할 수 있는 항체, 그의 변이체 및 그의 용도
|
|
AU2022344595A1
(en)
|
2021-09-13 |
2024-05-02 |
Janssen Biotech, Inc |
CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
|
|
EP4405396A2
(en)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
CN117813323A
(zh)
|
2021-09-23 |
2024-04-02 |
江苏恒瑞医药股份有限公司 |
抗klb抗体及用途
|
|
US20250019455A1
(en)
|
2021-09-24 |
2025-01-16 |
Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
|
US20240400670A1
(en)
|
2021-09-30 |
2024-12-05 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-il23 antibody fusion protein and uses thereof
|
|
JP7503215B2
(ja)
|
2021-10-08 |
2024-06-19 |
ジェンマブ エー／エス |
Ｃｄ３０及びｃｄ３に結合する抗体
|
|
EP4429706A1
(en)
|
2021-10-14 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
EP4416174A1
(en)
|
2021-10-14 |
2024-08-21 |
F. Hoffmann-La Roche AG |
New interleukin-7 immunoconjugates
|
|
WO2023069888A1
(en)
|
2021-10-18 |
2023-04-27 |
Tavotek Biotherapeutics (Hong Kong) Limited |
ANTI-EGFR ANTIBODIES, ANTI-cMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF
|
|
EP4426734A1
(en)
|
2021-11-01 |
2024-09-11 |
Janssen Biotech, Inc. |
Compositions and methods for the modulation of beta chain-mediated immunity
|
|
AU2022380722A1
(en)
|
2021-11-03 |
2024-06-20 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
CA3239224A1
(en)
|
2021-11-22 |
2023-05-25 |
Janssen Biotech, Inc. |
Compositions comprising enhanced multispecific binding agents for an immune response
|
|
EP4437344A1
(en)
|
2021-11-25 |
2024-10-02 |
F. Hoffmann-La Roche AG |
Quantification of low amounts of antibody sideproducts
|
|
US20230183360A1
(en)
|
2021-12-09 |
2023-06-15 |
Janssen Biotech, Inc. |
Use of Amivantamab to Treat Colorectal Cancer
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
WO2023122723A1
(en)
|
2021-12-23 |
2023-06-29 |
The Broad Institute, Inc. |
Panels and methods for diagnosing and treating lung cancer
|
|
WO2023139293A1
(en)
|
2022-01-24 |
2023-07-27 |
Novimmune Sa |
Composition and methods for the selective activation of cytokine signaling pathways
|
|
KR20240135663A
(ko)
|
2022-01-28 |
2024-09-11 |
젠맵 에이/에스 |
미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
|
|
US20230303693A1
(en)
|
2022-01-28 |
2023-09-28 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
US20250043022A1
(en)
|
2022-02-07 |
2025-02-06 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to psma and cd3, and pharmaceutical use thereof
|
|
TW202342057A
(zh)
|
2022-02-07 |
2023-11-01 |
美商健生生物科技公司 |
用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
|
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
|
JP2025508692A
(ja)
|
2022-02-11 |
2025-04-10 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
免疫複合体及びその使用
|
|
EP4490192A1
(en)
|
2022-03-07 |
2025-01-15 |
Novimmune S.A. |
Cd28 bispecific antibodies for targeted t cell activation
|
|
US12122850B2
(en)
|
2022-03-14 |
2024-10-22 |
LamKap Bio gamma AG |
Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
|
|
CA3245807A1
(en)
|
2022-03-14 |
2025-06-13 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Antigen-binding molecule specifically binding to GPRC5D and CD3 and its medical use
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
KR20240164782A
(ko)
|
2022-03-23 |
2024-11-20 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체와 화학요법의 병용 치료
|
|
TW202346337A
(zh)
|
2022-03-29 |
2023-12-01 |
美商恩格姆生物製藥公司 |
Ilt3及cd3結合劑以及其使用方法
|
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
KR20250004776A
(ko)
|
2022-04-13 |
2025-01-08 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체의 약학 조성물 및 사용 방법
|
|
JP2025513335A
(ja)
|
2022-04-19 |
2025-04-24 |
エフ． ホフマン－ラ ロシュ アーゲー |
改良された産生細胞
|
|
AR129136A1
(es)
|
2022-04-26 |
2024-07-17 |
Novartis Ag |
Anticuerpos multiespecíficos que se dirigen a il-13 e il-18
|
|
IL316628A
(en)
|
2022-05-12 |
2024-12-01 |
Genmab As |
Binding agents capable of binding to CD27 in combination therapy
|
|
WO2023218051A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
EP4522757A2
(en)
|
2022-05-13 |
2025-03-19 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
JP2025517572A
(ja)
|
2022-06-03 |
2025-06-05 |
エフ． ホフマン－ラ ロシュ アーゲー |
改良された産生細胞
|
|
AU2023287212A1
(en)
|
2022-06-23 |
2024-12-19 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to dll3 and cd3, and pharmaceutical use thereof
|
|
JP2025522814A
(ja)
|
2022-06-30 |
2025-07-17 |
ヤンセン バイオテツク，インコーポレーテツド |
胃癌又は食道癌を治療するための抗ｅｇｆｒ／抗ｍｅｔ抗体の使用
|
|
TW202435912A
(zh)
|
2022-08-03 |
2024-09-16 |
美商航海家醫療公司 |
用於穿過血腦屏障之組合物及方法
|
|
KR20250046283A
(ko)
|
2022-08-05 |
2025-04-02 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
Gucy2c 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이의 의약적 용도
|
|
KR20250069606A
(ko)
|
2022-09-15 |
2025-05-19 |
보이저 테라퓨틱스, 인크. |
타우 결합 화합물
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
|
CN120476144A
(zh)
|
2022-10-21 |
2025-08-12 |
诺夫免疫股份有限公司 |
用于免疫检查点依赖性T细胞活化的PD-L1xCD28双特异性抗体
|
|
WO2024089551A1
(en)
|
2022-10-25 |
2024-05-02 |
Janssen Biotech, Inc. |
Msln and cd3 binding agents and methods of use thereof
|
|
WO2024094660A1
(en)
|
2022-10-31 |
2024-05-10 |
Genmab A/S |
Cd38 antibodies and uses thereof
|
|
KR20250096769A
(ko)
|
2022-11-01 |
2025-06-27 |
상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 |
글리피칸-3에 대한 이중특이성 항체 및 이의 용도
|
|
AU2023375177A1
(en)
|
2022-11-02 |
2025-06-19 |
Janssen Biotech, Inc. |
Methods of treating cancers
|
|
EP4612179A1
(en)
|
2022-11-02 |
2025-09-10 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
JP2025539760A
(ja)
|
2022-11-15 |
2025-12-09 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合分子
|
|
EP4619427A1
(en)
|
2022-11-15 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Recombinant binding proteins with activatable effector domain
|
|
AU2023404602A1
(en)
|
2022-11-29 |
2025-05-29 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Cldn18.2/4-1bb binding protein and medical use thereof
|
|
CN120548192A
(zh)
|
2023-01-20 |
2025-08-26 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
|
CN120569410A
(zh)
|
2023-01-25 |
2025-08-29 |
豪夫迈·罗氏有限公司 |
与csf1r和cd3结合的抗体
|
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
|
TW202436339A
(zh)
|
2023-01-31 |
2024-09-16 |
瑞士商赫孚孟拉羅股份公司 |
治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
AU2024217296A1
(en)
|
2023-02-09 |
2025-09-25 |
Janssen Biotech, Inc. |
Anti-v beta 17/anti-cd123 bispecific antibodies
|
|
CN120826234A
(zh)
|
2023-03-06 |
2025-10-21 |
豪夫迈·罗氏有限公司 |
抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
|
|
CN120835901A
(zh)
|
2023-03-13 |
2025-10-24 |
豪夫迈·罗氏有限公司 |
采用pd1-lag3双特异性抗体和hla-g t细胞双特异性抗体的组合疗法
|
|
WO2024189544A1
(en)
|
2023-03-13 |
2024-09-19 |
Janssen Biotech, Inc. |
Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
|
|
CN120917044A
(zh)
|
2023-04-03 |
2025-11-07 |
豪夫迈·罗氏有限公司 |
激动性拆分型抗体
|
|
CN120882744A
(zh)
|
2023-04-03 |
2025-10-31 |
豪夫迈·罗氏有限公司 |
一体化激动性抗体
|
|
TW202506178A
(zh)
|
2023-04-05 |
2025-02-16 |
丹麥商珍美寶股份有限公司 |
包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物
|
|
KR20250163373A
(ko)
|
2023-04-11 |
2025-11-20 |
바이오레이 파마슈티컬 씨오., 엘티디. |
항-ror1 항체 및 그 약물 접합체
|
|
WO2024213754A1
(en)
|
2023-04-13 |
2024-10-17 |
Genmab A/S |
Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
|
|
AR132623A1
(es)
|
2023-05-08 |
2025-07-16 |
Hoffmann La Roche |
PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO
|
|
AR132668A1
(es)
|
2023-05-12 |
2025-07-16 |
Genmab As |
Anticuerpos capaces de unirse a ox40, variantes de los mismos y usos de los mismos
|
|
AR132687A1
(es)
|
2023-05-16 |
2025-07-23 |
Hoffmann La Roche |
Inmunoconjugados de il-2 regulados por pd-1 y sus usos
|
|
CA3228195A1
(en)
|
2023-05-23 |
2025-06-30 |
Janssen Biotech Inc |
Methods for treatment of non-small cell lung cancer (nsclc)
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
TW202509077A
(zh)
|
2023-06-30 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
與纖維母細胞活化蛋白α及死亡受體４結合之抗體
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
AR133412A1
(es)
|
2023-07-30 |
2025-09-24 |
Janssen Biotech Inc |
Moléculas que se unen a la calreticulina mutante y usos de estas
|
|
WO2025034715A1
(en)
|
2023-08-07 |
2025-02-13 |
Janssen Biotech, Inc. |
Gucy2c antibodies and uses thereof
|
|
US20250136688A1
(en)
|
2023-08-07 |
2025-05-01 |
Janssen Biotech, Inc. |
Stabilized cd3 antigen binding agents and methods of use thereof
|
|
WO2025032508A1
(en)
|
2023-08-07 |
2025-02-13 |
Janssen Biotech, Inc. |
Enpp3 and cd3 binding agents and methods of use thereof
|
|
WO2025032069A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025036892A1
(en)
|
2023-08-14 |
2025-02-20 |
Morphosys Ag |
Cycat halfbody molecules comprising sterically occluding moieties
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
WO2025052273A1
(en)
|
2023-09-05 |
2025-03-13 |
Janssen Biotech, Inc. |
Methods of treating non-small cell lung cancer
|
|
WO2025051895A1
(en)
|
2023-09-06 |
2025-03-13 |
Novimmune Sa |
Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025079020A1
(en)
|
2023-10-12 |
2025-04-17 |
Janssen Biotech, Inc. |
First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
|
|
WO2025082777A1
(en)
|
2023-10-17 |
2025-04-24 |
Morphosys Ag |
Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|
|
WO2025085610A1
(en)
|
2023-10-18 |
2025-04-24 |
Janssen Biotech, Inc. |
Combination treatment of prostate cancers with two bispecific antibodies
|
|
TW202535406A
(zh)
|
2023-10-30 |
2025-09-16 |
美商壯生和壯生企業創新公司 |
用於治療肺癌之a2a受體拮抗劑
|
|
WO2025114541A1
(en)
|
2023-11-30 |
2025-06-05 |
Genmab A/S |
Antibodies capable of binding to ox40 in combination therapy
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025120583A2
(en)
|
2023-12-08 |
2025-06-12 |
Janssen Biotech, Inc. |
CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025151018A1
(ko)
*
|
2024-01-12 |
2025-07-17 |
주식회사 노벨티노빌리티 |
C-kit 및 vegf에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
|
|
WO2025153988A1
(en)
|
2024-01-16 |
2025-07-24 |
Janssen Biotech, Inc. |
Use of amivantamab to treat colorectal cancer
|
|
WO2025158277A1
(en)
|
2024-01-22 |
2025-07-31 |
Janssen Biotech, Inc. |
Use of amivantamab to treat head and neck cancer
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025191459A1
(en)
|
2024-03-11 |
2025-09-18 |
Janssen Biotech, Inc. |
Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
WO2025221736A2
(en)
|
2024-04-15 |
2025-10-23 |
Janssen Biotech, Inc. |
Ltbr binding molecules and uses thereof
|
|
WO2025219504A1
(en)
|
2024-04-19 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|
|
WO2025226541A2
(en)
|
2024-04-26 |
2025-10-30 |
Janssen Biotech, Inc. |
Klk2xcd3 antibody and an anti-cancer agent for treating prostate cancer
|
|
WO2025231408A2
(en)
|
2024-05-03 |
2025-11-06 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma with car-t cells and bispecific antibodies
|
|
WO2025233825A1
(en)
|
2024-05-06 |
2025-11-13 |
Janssen Pharmaceutica Nv |
Enrichment of cells expressing a bird linker
|
|
WO2025237931A1
(en)
|
2024-05-15 |
2025-11-20 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
|
|
WO2025243243A1
(en)
|
2024-05-24 |
2025-11-27 |
Janssen Biotech, Inc. |
Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19
|
